Financial News
Biogen suffers setback after Alzheimer's drug fails to win support from FDA panel
November 06, 2020 at 16:40 PM EST
If fully approved, it would be the first drug to slow cognitive decline in people living with the disease and the first new treatment for Alzheimer's in nearly 20 years.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
